Men diagnosed with obstructive sleep apnea (OSA) may be candidates for testosterone replacement therapy (TRT) in some cases, but eligibility depends on severity, treatment status, and individual evaluation. The Endocrine Society's 2018 guideline recommends against starting TRT in men with untreated severe OSA (Bhasin et al., 2018). Men with mild-to-moderate OSA, or those already using CPAP therapy, may begin TRT after individualized evaluation and under close monitoring by a licensed provider. Sleep apnea and TRT share a two-way relationship that makes screening and testosterone testing a necessary first step. For clients using direct-pay lab services through Marek Diagnostics, knowing where these conditions overlap helps guide safer treatment decisions.
What Is The Connection Between Sleep Apnea And TRT?
Obstructive sleep apnea is a condition in which the upper airway collapses repeatedly during sleep, causing paused breathing, drops in blood oxygen, and fragmented sleep. OSA is common in adult men, and prevalence rises with age and body weight. The condition overlaps with low testosterone in both directions. OSA disrupts the sleep stages where testosterone is produced, and exogenous testosterone may worsen markers of disordered breathing in some men.
Observational data consistently show that men with moderate-to-severe OSA tend to have lower total testosterone than men without OSA, and the association appears to strengthen as apnea severity increases. That bidirectional relationship is the reason clinical guidelines address both conditions before prescribing.
How TRT Affects Breathing During Sleep
The most cited interventional data comes from a randomized, placebo-controlled trial of 67 obese men with severe OSA (Hoyos et al., 2012). Men receiving intramuscular testosterone undecanoate showed a worsened oxygen desaturation index (ODI) by 10.3 events per hour (95% CI 0.8-19.8, P=0.03) and more time with blood oxygen below 90% (6.1% increase, 95% CI 1.5-10.6, P=0.01) at 7 weeks compared with placebo.
By 18 weeks, that difference was no longer statistically significant.
That timeline is clinically relevant. The worsening appears time-limited and concentrated in the early weeks of therapy, at least in men with severe disease. The exact mechanism isn't settled. One theory holds that testosterone affects upper airway muscle tone and central respiratory drive. A confounding factor in the literature is body weight. Obesity is the primary risk factor for OSA, and several studies didn't control for BMI or body composition. The Hoyos trial enrolled only obese men, so the findings may not apply equally to leaner men with milder OSA.
Based on limited trial data, starting TRT in a man with severe, untreated OSA may carry a short-term risk of worsened nocturnal hypoxemia. That risk appeared to resolve by 18 weeks in the Hoyos trial, though more data are needed. Close monitoring in the early months of therapy is recommended.
What Guidelines Recommend Before Starting TRT
The Endocrine Society's 2018 clinical practice guideline recommends against starting testosterone therapy in men with untreated severe OSA (Bhasin et al., 2018). This applies to untreated severe disease. Men with mild-to-moderate OSA, or men whose severe OSA is being managed with CPAP, aren't categorically excluded.
The AUA's 2018 testosterone deficiency guideline (validity confirmed 2024) echoes this position (Mulhall et al., 2018). It calls for screening for OSA symptoms before starting therapy and counseling on the risk that TRT may worsen untreated sleep apnea. Both guidelines require two separate early-morning fasting total testosterone draws showing consistently low levels, combined with symptoms of deficiency, before a diagnosis is made.
In February 2025, the FDA issued class-wide labeling changes for all testosterone products (FDA, 2025). The update removed the previous cardiovascular boxed warning based on the TRAVERSE trial, which showed a neutral primary MACE endpoint (HR 0.96, 95% CI 0.78-1.17) in men with preexisting cardiovascular risk (Lincoff et al., 2023). The same trial reported higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group. The FDA added a strengthened blood-pressure warning. Testosterone products remain approved only for men with low levels from a diagnosed medical condition, not age-related decline alone.
How Does Sleep Apnea Lower Testosterone?
Most of a man's daily testosterone is secreted during sleep, with the highest release occurring during REM stages. OSA fragments sleep by causing repeated micro-awakenings and drops in oxygen saturation, cutting into the time spent in REM.
The result may be lower testosterone output. Multiple observational studies have found an inverse association between OSA severity and testosterone levels, with the relationship holding across markers including total testosterone and minimum oxygen saturation during sleep.
Weight compounds the problem. Obesity is both a primary risk factor for OSA and is associated with lower testosterone, in part through increased aromatization (conversion of testosterone to estradiol in fat tissue). This is sometimes called the hypogonadal-obesity cycle, where more body fat lowers testosterone and lower testosterone promotes further fat accumulation. Providers can track this with estradiol testing alongside testosterone panels.
Does CPAP Raise Testosterone Enough To Skip TRT?
Based on current evidence, CPAP alone doesn't appear to restore testosterone levels for most men. A 2014 meta-analysis of randomized trials found that CPAP therapy had a neutral effect on total and free testosterone levels (Zhang et al., 2014). A 2019 systematic review reached the same conclusion (Meston et al., 2019).
A small number of recent studies have reported partial exceptions. In one small subset of men with severe obesity who were adherent to CPAP for several months, testosterone showed a modest increase independent of BMI change. These are preliminary findings from small samples and haven't been replicated in larger trials.
CPAP can improve breathing, oxygen saturation, and sleep quality, but it doesn't reliably restore testosterone to normal range on its own. Men who have both OSA and confirmed testosterone deficiency (two morning draws with low levels per the AUA protocol, with symptoms) may still be candidates for TRT, based on individual evaluation by their provider. The standard approach is to treat or stabilize OSA first, then consider TRT with monitoring. Treatment decisions should be individualized and made in partnership between the client and a licensed provider.
Monitoring Markers When Both Conditions Overlap
When a man has OSA and is receiving TRT, certain lab markers may carry compounded risk. Hematocrit is among the most commonly monitored markers in this setting.
Both OSA and TRT are associated with increased red blood cell production. OSA contributes through intermittent hypoxia (the body may produce more red cells to compensate for low oxygen). TRT can stimulate erythropoiesis directly. Together, these effects may push hematocrit above safe thresholds faster than either condition would alone. Clinical guidelines recommend monitoring hematocrit and adjusting treatment if levels rise above guideline-recommended thresholds (Bhasin et al., 2018; Mulhall et al., 2018).
Monitoring plans are individualized. The markers below are commonly discussed in clinical guidelines and are not a substitute for provider-directed care.
|
Marker |
Why It May Matter With Both Conditions |
Monitoring Frequency |
|
Hematocrit / CBC |
Both OSA and TRT are associated with higher red cell counts; combined polycythemia risk |
Per provider direction |
|
Blood pressure |
FDA added a blood-pressure warning to TRT labels (Feb 2025); OSA may raise BP independently |
Per provider direction |
|
Oxygen desaturation |
TRT may worsen nocturnal hypoxemia early in therapy (Hoyos et al., 2012) |
Per provider direction, if symptoms change |
|
Estradiol (E2) |
Higher testosterone levels may increase aromatization, which can affect fluid retention |
Per provider direction |
|
PSA |
Commonly included in TRT monitoring panels |
Per provider direction |
Before starting TRT, providers often use the STOP-BANG questionnaire, a validated screening tool that scores sleep apnea risk based on snoring, tiredness, observed apnea, blood pressure, BMI, age, neck circumference, and sex. High-scoring men may be referred for a sleep study (polysomnography or a home sleep apnea test) to confirm the diagnosis and severity before therapy begins.
Clients can prep for a blood draw by fasting and scheduling between 7 and 10 a.m. for accurate testosterone results. A pre-therapy panel covers total testosterone, free testosterone, hematocrit, PSA, and SHBG, giving the provider a baseline before treatment starts. Tracking monitoring biomarkers over time helps providers adjust treatment based on lab trends.
Weight Loss And Its Role In Both Conditions
Excess body weight is one of the strongest modifiable risk factors for both OSA and low testosterone. Fat tissue around the neck may increase airway obstruction during sleep. Fat tissue elsewhere may increase aromatization, converting testosterone to estradiol and potentially lowering free testosterone.
Losing weight can reduce the apnea-hypopnea index (a measure of OSA severity) and raise testosterone at the same time. Clinical observation suggests even modest reductions in body weight can improve both conditions, though individual results vary. Resistance training and caloric management often appear in treatment plans alongside TRT and CPAP.
For clients tracking progress over time, bundled lab panels through Marek Diagnostics cover testosterone, hematocrit, metabolic markers, and estradiol, measuring change across both conditions. Understanding how testing works is the first step for men managing sleep apnea and TRT at the same time.
Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.
FAQs
Can someone with sleep apnea start TRT safely?
The Endocrine Society guideline recommends against starting TRT in men with untreated severe OSA (Bhasin et al., 2018). Men with mild-to-moderate OSA, or severe OSA being managed with CPAP, may be candidates for TRT with appropriate monitoring. The provider evaluates OSA severity and treatment status on an individual basis before prescribing.
Does TRT cause new sleep apnea in men who don't already have it?
Evidence is stronger for worsening existing severe OSA than for causing new disease in low-risk men. Some cohort data show a modestly higher incidence of OSA in TRT users, but the effect appears modest and time-limited based on available trial data (Hoyos et al., 2012).
How are sleep apnea and TRT managed at the same time?
Providers typically treat or stabilize OSA first, often with CPAP therapy, before starting TRT. Once therapy begins, hematocrit, blood pressure, and sleep symptoms are monitored at regular intervals. If OSA symptoms worsen, dose adjustment or a follow-up sleep study may be needed.
Should every man get a sleep study before starting TRT?
Not every man requires a formal polysomnography. Guidelines support screening for OSA symptoms using validated tools like the STOP-BANG questionnaire. Men who score high or have known risk factors (obesity, loud snoring, observed apnea episodes) are then referred for testing before therapy starts.
Can weight loss improve both sleep apnea and testosterone levels?
Yes. Excess body fat is associated with higher OSA risk and may lower testosterone through increased aromatization. Clinical data suggest that weight loss may reduce OSA severity and support healthier testosterone levels. Even modest reductions in body weight can improve both conditions, though individual results vary.
Does having sleep apnea and TRT together increase the risk of high hematocrit?
Both conditions are associated with increased red blood cell production. OSA may contribute through intermittent hypoxia, and TRT can stimulate erythropoiesis directly. Together, the risk of polycythemia may be compounded. Regular monitoring is a standard part of the treatment protocol when both conditions are present.
What is the STOP-BANG questionnaire used for before TRT?
STOP-BANG is a validated screening tool that scores sleep apnea risk based on snoring, tiredness, observed apnea, blood pressure, BMI, age, neck circumference, and sex. Providers use it to identify men who need a formal sleep study before starting testosterone therapy. It takes a few minutes and doesn't require equipment.
Share:
What An Estrogen Urine Test Tells You About Your Hormones
TRT Mood Changes: Why They Happen And What To Know